A perspective view of sodium iodide symporter research and its clinical implications, Eur. J. Endocrinol, vol.155, pp.495-512, 2006. ,
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer, Endocr. Relat. Cancer, vol.13, pp.797-826, 2006. ,
Immunohistochemical profile of the sodium/ iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections, J. Clin. Endocrinol. Metab, vol.88, pp.1880-1888, 2003. ,
The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance, Endocr. Rev, vol.24, pp.48-77, 2003. ,
Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression, J. Endocrinol, vol.167, pp.125-135, 2000. ,
Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin, J. Biol. Chem, vol.276, pp.21458-21463, 2001. ,
Hormonal regulation of radioiodide uptake activity and Na+/I-symporter expression in mammary glands, J. Clin. Endocrinol. Metab, vol.85, pp.2936-2943, 2000. ,
Taking up iodide in breast tissue, Nature, vol.406, pp.688-689, 2000. ,
Systematic Review of Trends in the Incidence Rates of Thyroid Cancer, Thyroid, vol.26, pp.1541-1552, 2016. ,
The changing incidence of thyroid cancer, Nat. Rev. Endocrinol, vol.12, pp.646-653, 2016. ,
Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrine Surgery and Head and Neck Surgery, pp.162-175, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01760914
American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid, vol.26, pp.1-133, 2015. ,
Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors, Cancer, vol.103, pp.1330-1335, 2005. ,
Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution, Ann. Oncol, vol.20, pp.1728-1735, 2009. ,
Approach to and treatment of differentiated thyroid carcinoma, Med. Clin. North Am, vol.96, pp.369-383, 2012. ,
Progress in molecular-based management of differentiated thyroid cancer, Lancet, vol.381, pp.1058-1069, 2013. ,
Radioactive iodinerefractory differentiated thyroid cancer: an uncommon but challenging situation, Arch. Endocrinol. Metab, vol.61, pp.81-89, 2017. ,
The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland, Thyroid, vol.22, pp.884-889, 2012. ,
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J. Clin. Endocrinol. Metab, vol.91, pp.2892-2899, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00176664
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J. Clin. Endocrinol. Metab, vol.91, pp.498-505, 2006. ,
Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects, Thyroid, vol.29, pp.311-321, 2019. ,
Expression of the Na+/I-symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes, J. Clin. Endocrinol. Metab, vol.84, pp.3228-3234, 1999. ,
Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma, Eur. J. Endocrinol, vol.150, pp.269-276, 2004. ,
Correlation of BRAFV600E mutation and glucose metabolism in thyroid Cancer patients: an (1)(8) F-FDG PET study, J. Nucl. Med, vol.56, pp.662-667, 2015. ,
, Cancer genome Atlas Research, integrated genomic characterization of papillary thyroid carcinoma, Cell, vol.159, pp.676-690, 2014.
Biologic and clinical perspectives on thyroid Cancer, N. Engl. J. Med, vol.375, p.2307, 2016. ,
Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer, J. Nucl. Med, vol.59, pp.780-786, 2018. ,
Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer, Endocr. J, vol.56, pp.105-112, 2009. ,
Redifferentiation of radioiodine refractory differentiated thyroid Cancer for reapplication of I-131 therapy, Front. Endocrinol. (Lausanne), vol.8, p.260, 2017. ,
Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma, Thyroid, vol.16, pp.1025-1031, 2006. ,
Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation, Mol. Cell. Endocrinol, vol.348, pp.260-269, 2012. ,
Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation, Cancer Gene Ther, vol.22, pp.410-416, 2015. ,
Selumetinibenhanced radioiodine uptake in advanced thyroid cancer, N. Engl. J. Med, vol.368, pp.623-632, 2013. ,
Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib, Clin. Cancer Res, vol.21, pp.1028-1035, 2015. ,
, Nat. Commun, vol.8, p.1903, 2017.
The effects of cholesterol-derived oncometabolites on nuclear receptor function in Cancer, Cancer Res, vol.78, pp.4803-4808, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02380550
The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers, Biochem. Pharmacol, vol.153, pp.75-81, 2018. ,
Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties, Nat. Commun, vol.4, p.1840, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00823974
Ligand-dependent transcriptional induction of lethal autophagy: a new perspective for cancer treatment, Autophagy, vol.14, pp.555-557, 2018. ,
Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases, J. Med. Chem, vol.52, pp.7765-7777, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00519151
Dendrogenin a: a mammalian metabolite of cholesterol with tumor suppressor and neurostimulating properties, Curr. Med. Chem, vol.22, pp.3533-3549, 2015. ,
When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metabolite, Biochem. Soc. Trans, vol.44, pp.631-637, 2016. ,
From tamoxifen to dendrogenin A: the discovery of a mammalian tumor suppressor and cholesterol metabolite, Biochimie, vol.130, pp.109-114, 2016. ,
Iodide transport in a continuous line of cultured cells from rat thyroid, Endocrinology, vol.114, pp.1090-1098, 1984. ,
Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions, Mol. Endocrinol, vol.24, pp.1287-1296, 2010. ,
Thyroid cancer cell lines: an overview, Front. Endocrinol, p.133, 2012. ,
Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer, Cancer Gene Ther, vol.8, pp.612-618, 2001. ,
The prevalence and prognostic value of BRAF mutation in thyroid cancer, Ann. Surg, vol.246, pp.466-470, 2007. ,
Liver X receptors as regulators of metabolism, Biomol. Concepts, vol.6, pp.177-190, 2015. ,
Liver X receptor beta controls thyroid hormone feedback in the brain and regulates browning of subcutaneous white adipose tissue, Proc. Natl. Acad. Sci. U S A, vol.112, pp.14006-14011, 2015. ,
, Journal of Steroid Biochemistry and Molecular Biology, vol.192, p.105390, 2019.